Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4606498 | 0.89 | LRRK2 (0.52) | LRRK2PDE4BCSF1RPDGFRA | |
| SCHEMBL4606431 | 0.89 | PDE4B (0.44) | LRRK2PDE4BRIPK2KCNH2CSF1R | |
| SCHEMBL4606861 | 0.87 | LRRK2 (0.43) | LRRK2PDE4BCSF1RPDGFRA | |
| SCHEMBL4607569 | 0.86 | PDE4B (0.47) | LRRK2PDE4BCSF1RPDGFRA | |
| SCHEMBL4607834 | 0.84 | PDE4B (0.39) | LRRK2PDE4BBTKCSF1R | |
| SCHEMBL4608326 | 0.79 | LRRK2 (0.55) | LRRK2PDE4BCSF1RPDGFRA | |
| SCHEMBL4607763 | 0.77 | PDE4B (0.56) | LRRK2PDE4BCSF1RPDGFRA | |
| SCHEMBL4608176 | 0.76 | PDE4B (0.45) | LRRK2PDE4BCSF1RPDGFRA | |
| SCHEMBL4607823 | 0.75 | PDE4B (0.44) | LRRK2PDE4BCSF1RPDGFRA | |
| SCHEMBL4608691 | 0.75 | PDE4B (0.58) | LRRK2PDE4BCSF1RPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | claimed |
| EP-1945616-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2008-07-23 | — | — | EP | claimed |
| WO-2007045861-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2007-04-26 | — | — | WO | claimed |
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | PDE4A, PDE4B, PDE3B | LRRK2 2855/4885PDE4B 2/4885RIPK2 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.